Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma

World Journal of Gastroenterology

Volumn 14, Issue 25, 2008, Pages 4082-4086

  Cai, Hong Yi ^a   Wang, Xiao Hu ^a   Tian, Ying ^a   Gao, Li Ying ^a   Zhang, Li Juan ^a   Zhang, Zhi Yan ^a  

^a GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Enzyme linked immunosorbent assay; Esophageal carcinoma; Radiotherapy; Serum p53 antibodies

Indexed keywords

PROTEIN ANTIBODY; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE; SEX; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TUMOR LOCALIZATION; TUMOR VOLUME; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESOPHAGUS TUMOR; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TIME; TREATMENT OUTCOME;

AGED; AUTOANTIBODIES; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 53449089333     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4082     Document Type: Article

References (27)

1. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403-408
2. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168-4174
3. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52: 6380-6384
4. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994; 58: 480-487
5. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 2003; 97: 682-689
6. Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993; 53: 3468-3471
7. von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VM, Bennett WP, Liang L, He AG, Zhu SM, Tursz T, Janin N, Trivers GE. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 1996; 56: 4917-4921
8. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994; 69: 1115-1119
9. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995; 345: 621-622
10. Sato S, Kigawa J, Minagawa Y, Okada M, Shimada M, Takahashi M, Kamazawa S, Terakawa N. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 1999; 86: 1307-1313
11. Nasierowska-Guttmejer A, Szawlowski A, Jastrzebska M, Jeziorski K, Radziszewski J. p53 Protein accumulation as a prognostic marker of preoperative radiotherapy and/or chemotherapy in advanced squamous cell esophageal carcinoma - preliminary report. Dis Esophagus 1999; 12: 128-131
12. Zhao KL, Wang Y, Shi XH. Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma. World J Gastroenterol 2003; 9: 1374-1376
13. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52
14. Levine AJ. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 1990; 177: 419-426
15. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16
16. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979-2984
17. Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, Gown AM. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer. Eur J Gynaecol Oncol 1996; 17: 487-492
18. Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Gagetti O, Bevilacqua G, Genazzani AR. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol 1999; 72: 76-81
19. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90: 4961-4965
20. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245
21. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, Lohrs U. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996; 105: 341-349
22. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995; 76: 1201-1208
23. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994; 53: 301-306
24. Green JA, Robertson LJ, Campbell IR, Jenkins J. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 1995; 19: 151-155
25. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, Hayashi H, Takeda A, Ochiai T. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002; 132: 41-47
26. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 1998; 77: 1848-1851
27. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992; 89: 3439-3442